



## LAAT-1 Is the Lysosomal Lysine/Arginine Transporter That Maintains Amino Acid Homeostasis

Bin Liu *et al.*

*Science* **337**, 351 (2012);

DOI: 10.1126/science.1220281

*This copy is for your personal, non-commercial use only.*

If you wish to distribute this article to others, you can order high-quality copies for your colleagues, clients, or customers by [clicking here](#).

Permission to republish or repurpose articles or portions of articles can be obtained by following the guidelines [here](#).

**The following resources related to this article are available online at [www.sciencemag.org](http://www.sciencemag.org) (this information is current as of February 17, 2014):**

**Updated information and services**, including high-resolution figures, can be found in the online version of this article at:

<http://www.sciencemag.org/content/337/6092/351.full.html>

**Supporting Online Material** can be found at:

<http://www.sciencemag.org/content/suppl/2012/07/19/337.6092.351.DC1.html>

This article **cites 42 articles**, 22 of which can be accessed free:

<http://www.sciencemag.org/content/337/6092/351.full.html#ref-list-1>

This article has been **cited by 5 articles** hosted by HighWire Press; see:

<http://www.sciencemag.org/content/337/6092/351.full.html#related-urls>

This article appears in the following **subject collections**:

Cell Biology

[http://www.sciencemag.org/cgi/collection/cell\\_biol](http://www.sciencemag.org/cgi/collection/cell_biol)

munities under varying levels of disturbance. An ecosystem under more-intensive disturbance is expected to have a more stabilizing composition of interaction types.

Species diversity has been of primary interest in understanding the role of biodiversity in ecosystem maintenance (24, 27), and a major focus of biodiversity conservation. The present study sheds new light on another aspect of biodiversity: diversity in interaction types. We determined that biodiversity in species and interactions is integral to stabilizing biological communities, which has important implications for biodiversity conservation. Species loss is of vital conservation concern; however, we may also need to identify the interaction types lost or maintained for two primary reasons. First, a complex community may be self-sustaining only in the presence of different interaction types. Therefore, a biased loss of one interaction type may critically destabilize the complex ecosystem. Second, the multiple interaction types can change the complexity-stability effect. The positive complexity-stability relationship of hybrid communities implies that a hybrid community is self-sustaining. However, it should be noted that such a self-sustaining community is more vulnerable to cascading biodiversity losses;

a simplified community can destabilize population dynamics and enhance additional species losses.

#### References and Notes

- R. M. May, *Nature* **238**, 413 (1972).
- A.-M. Neutel, J. A. P. Heesterbeek, P. C. De Ruiter, *Science* **296**, 1120 (2002).
- U. Brose, R. J. Williams, N. D. Martinez, *Ecol. Lett.* **9**, 1228 (2006).
- N. D. Martinez, R. J. Williams, J. A. Dunne, in *Ecological Networks: Linking Structure to Dynamics in Food Webs*, M. Pascual, J. A. Dunne, Eds. (Oxford Univ. Press, Oxford, 2006), pp. 163–185.
- J. Bascompte, P. Jordano, J. M. Olesen, *Science* **312**, 431 (2006).
- T. Okuyama, J. N. Holland, *Ecol. Lett.* **11**, 208 (2008).
- S. Allesina, D. Alonso, M. Pascual, *Science* **320**, 658 (2008).
- E. Thébault, C. Fontaine, *Science* **329**, 853 (2010).
- S. L. Pimm, *Food Webs* (Chapman and Hall, London, 2002).
- J. N. Thompson, *Science* **312**, 372 (2006).
- J. M. Chase *et al.*, *Ecol. Lett.* **5**, 302 (2002).
- S. Y. Strauss, R. E. Irwin, *Annu. Rev. Ecol. Syst.* **35**, 435 (2004).
- K. D. Lafferty *et al.*, *Ecol. Lett.* **11**, 533 (2008).
- C. J. Melián *et al.*, *Oikos* **118**, 122 (2009).
- C. Fontaine *et al.*, *Ecol. Lett.* **14**, 1170 (2011).
- J. F. Addicott, H. I. Freedman, *Theor. Popul. Biol.* **26**, 320 (1984).

- M. S. Ringel, H. H. Hu, G. Anderson, M. S. Ringel, *Theor. Popul. Biol.* **50**, 281 (1996).
- S. Allesina, M. Pascual, *Theor. Ecol.* **1**, 55 (2008).
- S. Allesina, S. Tang, *Nature* **483**, 205 (2012).
- X. Chen, J. E. Cohen, *Proc. Biol. Sci.* **268**, 869 (2001).
- F. Zhang, C. Hui, J. S. Terblanche, *Ecol. Lett.* **14**, 797 (2011).
- S. E. Townsend, D. T. Haydon, L. Matthews, *J. Theor. Biol.* **267**, 243 (2010).
- See supplementary materials text on Science Online.
- K. S. McCann, *Nature* **405**, 228 (2000).
- A. R. Ives, S. R. Carpenter, *Science* **317**, 58 (2007).
- S. L. Pimm, *The Balance of Nature?* (Univ. of Chicago Press, Chicago, 1991).
- M. Loreau *et al.*, *Science* **294**, 804 (2001).

**Acknowledgments:** This work was supported by the Environment Research and Technology Development Fund (grant D-1102) of the Ministry of the Environment, Japan; a Grant-in-Aid for Scientific Research (B) (no. 20370012); and a Grant-in-Aid for Challenging Exploratory Research (no. 23657019, 30388160) of the Japan Society for the Promotion of Science. The authors declare no competing financial interests.

#### Supplementary Materials

www.sciencemag.org/cgi/content/full/337/6092/349/DC1  
Supplementary Text  
Figs. S1 to S8

14 February 2012; accepted 25 May 2012  
10.1126/science.1220529

# LAAT-1 Is the Lysosomal Lysine/Arginine Transporter That Maintains Amino Acid Homeostasis

Bin Liu,<sup>1,4\*</sup> Hongwei Du,<sup>2,3,4\*</sup> Rachael Rutkowski,<sup>5†</sup> Anton Gartner,<sup>5</sup> Xiaochen Wang<sup>4‡</sup>

Defective catabolite export from lysosomes results in lysosomal storage diseases in humans. Mutations in the cystine transporter gene *CTNS* cause cystinosis, but other lysosomal amino acid transporters are poorly characterized at the molecular level. Here, we identified the *Caenorhabditis elegans* lysosomal lysine/arginine transporter LAAT-1. Loss of *laat-1* caused accumulation of lysine and arginine in enlarged, degradation-defective lysosomes. In mutants of *ctns-1* (*C. elegans* homolog of *CTNS*), LAAT-1 was required to reduce lysosomal cystine levels and suppress lysosome enlargement by cysteamine, a drug that alleviates cystinosis by converting cystine to a lysine analog. LAAT-1 also maintained availability of cytosolic lysine/arginine during embryogenesis. Thus, LAAT-1 is the lysosomal lysine/arginine transporter, which suggests a molecular explanation for how cysteamine alleviates a lysosomal storage disease.

Defects in exporting hydrolytic degradation products from lysosomes cause lysosomal storage diseases such as cystinosis, which is characterized by intralysosomal accumulation of free cystine because of mutations in the lysosomal cystine transporter gene *CTNS* (cystinosis) (1–4). The most effective therapeutic agent for cystinosis, cysteamine (an aminothioliol), converts lysosomal free cystine to cysteine and the mixed disulfide of cysteine-cysteamine, which is thought to be exported from lysosomes as a lysine analog through a lysine/cationic amino acid transporter (5–7). The molecular identity of the transporter remains unknown. Although biochemically detected, most mammalian lysosomal

amino acid transporters have not been molecularly characterized (1).

From a forward genetic screen for *Caenorhabditis elegans* mutants with increased embryonic cell corpses, we isolated a recessive mutant *qx42* that accumulated many refractile corpse-like objects and lysotracker-positive puncta, suggestive of abnormal lysosomes (fig. S1, A to G). Using NUC-1::mCherry, which labels lysosomes (8, 9), or lysotracker staining, we found that *qx42* lysosomes were on average twice the volume of wild type (1.3 versus 0.5  $\mu\text{m}^3$ ) (Fig. 1, A to F''', and fig. S1, H to K).

We next examined whether *qx42* affected lysosomal cargo degradation. Apoptotic cells are


phagocytosed, then degraded in lysosomes. Cell death and cell corpse engulfment were normal in *qx42* mutants (fig. S2). However, degradation of apoptotic cells in phagolysosomes (indicated by GFP::RAB-7 or NUC-1::mCherry) as measured by loss of HIS-24::GFP or H2B::GFP (which label chromatin in all somatic and germ nuclei, including cell corpses, respectively) was severely affected in *qx42* mutants, with HIS-24::GFP persisting >4 times as long as in wild type (Fig. 2A and fig. S2, L to O). Yolk lipoprotein is degraded throughout embryogenesis to nourish developing cells (10, 11). In *qx42* mutants, intestinal secretion of yolk reporter VIT-2::GFP and uptake by oocytes were normal (fig. S3, A to B'). However, *qx42* embryos accumulated significantly more VIT-2::GFP in enlarged puncta, which overlapped with NUC-1::mCherry, suggesting defective lysosomal yolk degradation (Fig. 2, B to D, and fig. S3, C to H'). Cell surface proteins CAV-1 and RME-2, which are internal-

<sup>1</sup>Graduate Program in Chinese Academy of Medical Sciences and Peking Union Medical College, China. <sup>2</sup>State Key Laboratory of Molecular and Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China. <sup>3</sup>Graduate School, Chinese Academy of Sciences, Beijing 100039, China. <sup>4</sup>National Institute of Biological Sciences, No. 7 Science Park Road, Zhongguancun Life Science Park, Beijing 102206, China. <sup>5</sup>Wellcome Trust Centre for Gene Regulation and Expression, College of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.

\*These authors contributed equally to this work.

†Present address: Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3052, Australia.


‡To whom correspondence should be addressed. E-mail: wangxiaochen@nibs.ac.cn



**Fig. 1.** *laa-1* mutants accumulate enlarged lysosomes. (A to F'') Enlarged lysosomes indicated by NUC-1::mCherry (A) and (B), arrows) or lysotracker red (LTR) [(E) to (F''), arrowheads] were observed in a *laa-1(qx42)* embryo (B) or cell [(F) to (F'')] but not wild type [(A) and (E) to (E'')]. Lysosome volumes are quantified in (C) and (D). Average lysosomal volumes ( $\pm$ SEM,  $n = 100$ ) in different strains are shown in (D).  $**P < 0.0001$ . (G and H) Fluorescent images of hypodermal (G) or sheath (H) cells in wild-type animals expressing LAAT-1::GFP and

NUC-1::mCherry. In (A), (B), and (G) to (H''), insets show 4 $\times$  magnification of lysosomes indicated by yellow arrows. Scale bars: 2  $\mu\text{m}$  in (E) and (F); 5  $\mu\text{m}$  in other panels.

**Fig. 2.** *laa-1* mutants are defective in lysosomal degradation of various cargoes. (A) Fluorescent images of wild-type and *laa-1(qx42)* embryos expressing HIS-24::GFP and GFP::RAB-7 at different time points. Arrows indicate phagolysosomes. Quantification is shown in the right panel, with average duration ( $\pm$ SEM) shown in parentheses. (B to G) Confocal fluorescent images of wild-type [(B) and (E)] or *laa-1(qx42)* [(C) and (F)] embryos expressing NUC-1::mCherry and VIT-2::GFP [(B) and (C)] or T12G3.1::GFP [(E) and (F)]. Arrows indicate overlapping GFP and mCherry; arrowheads indicate nonoverlapping GFP. Structures indicated by yellow arrows or arrowheads are magnified 4 $\times$  in the insets. Quantifications are shown in (D) and (G). At least 10 embryos were scored in each strain. Data are shown as mean  $\pm$  SEM.  $**P < 0.0001$ . Scale bars, 5  $\mu\text{m}$ .



ized and degraded in wild-type embryos, accumulated in enlarged lysosomes in *qx42* embryos (fig. S4) (12). Damaged organelles and protein aggregates are delivered via the autophagy pathway to lysosomes for degradation (13). Autophagy substrates SEPA-1 and T12G3.1 (the *C. elegans* homolog of mammalian p62) were cleared during embryogenesis in wild type but persisted in late-stage *qx42* mutant embryos and overlapped with NUC-1::mCherry, indicating defective autolysosomal degradation (Fig. 2, E to G, and fig. S5)


(14, 15). Thus, *qx42* impairs lysosomal degradation of phagocytic, endocytic, and autophagic cargoes.

The gene affected in *qx42*, *Y43H11AL.2*, encodes a conserved protein containing seven predicted transmembrane domains and two internal PQ (Proline-Glutamine) loop repeats, characteristic of lysosomal cystine transporters (LCTs) (16) (fig. S6F). Cystinosin, the archetypal LCT family member, is a lysosomal cystine transporter, the abnormal function of which causes cystinosis (4). We named the *Y43H11AL.2* gene *laat-1* (lysosomal


al amino acid transporter 1) based on similarity with LCT family proteins and cellular functions (see below). *qx42* has an A>T mutation in *laat-1* that creates a premature stop codon after Asn<sup>127</sup>. Other independently isolated *laat-1* mutant alleles also caused enlarged lysosome and persistent cell corpse phenotypes (figs. S1, L to R, and S2K). *laat-1* was expressed in various cell types in embryos, larvae, and adults (fig. S7). GFP or mCherry fusion of LAAT-1, which fully rescued *qx42* defects (fig. S6, A to E), labeled membranes of NUC-1- or lysotracker-positive structures and overlapped with lysosomal membrane protein CTNS-1, the *C. elegans* homolog of human cystinosin (17), indicating that LAAT-1 localizes to lysosomal membranes (Fig. 1, G to H", and fig. S7, A to C"). LAAT-1( $\Delta$ 299-304)::GFP, which lacks the C-terminal dileucine-based lysosomal sorting motif (18), stained plasma membranes instead of lysosomes and failed to rescue *laat-1*(*qx42*) mutant phenotypes, indicating that LAAT-1 function depends on its lysosomal localization (figs. S6, A to F, and S7, D to E").

We examined lysosomes purified from *C. elegans* embryos (fig. S8) and found that loss of CTNS-1 caused cystine accumulation, suggesting that CTNS-1 mediates cystine efflux from lysosomes like human cystinosin (Fig. 3A). In *laat-1* mutant lysosomes, cystine levels were normal, but lysine and arginine levels were 16 and 8 times as higher as wild type, respectively, suggesting that LAAT-1 exports lysine and arginine from lysosomes (Fig. 3A and fig. S9A). Macrophage-like coelomocytes from *ctns-1* mutants contained huge granules (>6.5  $\mu$ m in diameter), which accumulated endocytosed cargo Cherry and were labeled by lysosomal membrane protein CUP-5 but not endosomal protein RME-8, indicating that they are enlarged lysosomes (19, 20) (Fig. 3, B and C, and fig. S9B). Most wild-type and *laat-1*(*qx42*) coelomocytes contained small lysosomes (<4.5  $\mu$ m) or 2 to 3 bigger ones (4.5 to 6.5  $\mu$ m) (Fig. 3C). Cysteamine treatment of *ctns-1* mutants greatly reduced lysosomal cystine accumulation and almost completely suppressed the enlarged lysosome phenotype (Fig. 3, C and D). In *laat-1*(*qx42*) *ctns-1*(*ok813*) double mutants, however, cysteamine failed to deplete lysosomal cystine and suppress enlarged lysosomes, which accumulated high levels of cystine and the lysine analog mixed disulfide of cysteine-cysteamine (Fig. 3, C to E). These data strongly suggest that LAAT-1 transports lysine out of lysosomes.

We investigated whether LAAT-1 or its human counterpart PQLC2 transported lysine and arginine using a whole cell-based transporter assay (4). Wild-type PQLC2::GFP localized to lysosomes in COS-7 cells, while PQLC2(ALL)::GFP, which lacks the lysosomal sorting motif, associated with plasma membranes, indicating that PQLC2 is a lysosomal membrane protein like LAAT-1 (fig. S6F and fig. S9, C to H"). Expression of plasma membrane-targeted LAAT-1 [LAAT-1( $\Delta$ 299-304)::GFP] or PQLC2 [PQLC2(ALL)::GFP] caused increased uptake of lysine and



**Fig. 3.** LAAT-1 is a lysosomal lysine and arginine transporter. **(A)** The ratio of amino acid concentration in lysosomal versus cytosolic fractions prepared from embryonic lysates was determined and normalized as 1 fold in wild type (y axis). **(B)** Differential interference contrast (DIC) and fluorescent images of wild-type and *ctns-1*(*ok813*) coelomocytes expressing secreted Cherry (ssCherry) and the lysosomal marker GFP::CUP-5. Lysosomes are labeled by Cherry and CUP-5 (arrows). Insets show lysosomes indicated by yellow arrows. Scale bars, 5  $\mu$ m. Quantification is shown in **(C)**. **(D)** and **(E)** Cystine (**D**) and mixed disulfide of cysteine-cysteamine (**E**) was determined in purified lysosomal fractions (PLF) after cysteamine treatment and normalized as 1 fold in wild type. **(F)** and **(G)** Lysine and arginine uptake was determined in **(F)** LAAT-1- or **(G)** PQLC2-expressing COS-7 cells. Data are shown as mean  $\pm$  SEM. \*\* $P < 0.0001$ ; \* $P < 0.05$ ; all other points had  $P > 0.05$ . Data in **(A)**, **(D)**, **(E)**, **(F)**, and **(G)** are representative of three independent experiments.



**Fig. 4.** LAAT-1 maintains lysine and arginine availability for normal embryonic development. (A and B) Retarded embryonic development in *laa-1* mutants is rescued by external lysine and arginine supplements. At least 88 embryos were examined. (C) Protein synthesis rates determined by fluorescence recovery after photobleaching in wild-type, *laa-1(qx42)*, and *laa-1(qx111)* embryos expressing  $P_{laa-1}$ mCherry with or without externally supplied lysine and arginine. At least 20 embryos were quantified in each strain and treatment. (D) Loss of *laa-1* and *gcn-2* causes synthetic embryonic lethality. The y axis indicates the percentage of viable embryos in each strain and treatment. Three independent experiments were performed with at least 95 embryos examined in each. In panels (C) and (D), data are shown as mean  $\pm$  SEM. **\*\*** $P < 0.0001$ . In panels (B) to (D), lysine (K) and arginine (R) were supplied at 100 mM each, and glycine (G) was supplied at 200 mM.

which was almost completely abolished when the invariant Pro in the first PQ loop was mutated to Leu (Fig. 3, F and G, and fig. S6F). Uptake of histidine, but not alanine, glutamic acid, cystine, or cysteine, was increased in LAAT-1- or PQLC2-expressing cells, suggesting specific transport of cationic amino acids (fig. S10). *laa-1* lysosomes did not significantly accumulate histidine, indicating that LAAT-1 is probably not the major histidine transporter in vivo (fig. S9A).

*laa-1* mutants were viable but developed slowly (Fig. 4A). External supplements of both lysine and arginine completely rescued retarded embryonic development (Fig. 4B and fig. S11, A and B) but did not reverse the enlarged lysosome or defective yolk degradation phenotypes in *laa-1* mutants (fig. S11C). Thus, loss of *laa-1* affects lysosomal export of lysine/arginine, which limits their cytoplasmic availability and thereby retards embryonic development. When deprived of amino acids, eukaryotic cells trigger the amino acid response (AAR) pathway through activation of GCN2 protein kinase, leading to repression of global protein synthesis (21). Consistent with this, *laa-1* embryos showed reduced protein synthesis, which was efficiently rescued by supplementing lysine and arginine (Fig. 4C and fig. S11D) (22). The AAR pathway is essential for survival during amino acid deprivation (23, 24). *gcn-2(ok871)* embryos developed normally but died when *laa-1* was defective. The synthetic lethality was completely rescued by supplying both lysine and arginine but not glycine (Fig. 4D). Thus, loss of *laa-1* limits cytosolic lysine and arginine, causing embryonic lethality when the GCN2-mediated AAR pathway is impaired (fig. S11E).

We have identified LAAT-1 and its human homolog PQLC2 as the lysosomal lysine/arginine transporter. Cysteamine treatment significantly reduced lysosomal free cystine and efficiently suppressed the enlarged lysosome phenotype in *ctns-1(lf)* single mutants but not *laa-1(lf)ctns-1(lf)* double mutants, which accumulated the lysine analog mixed disulfide of cysteine-cysteamine in lysosomes, suggesting that LAAT-1 (and probably PQLC2) may mediate cystine depletion by cysteamine. It is thus important to examine whether loss of PQLC2 affects mammalian lysosome function and causes lysosome-related diseases. Our finding that defective lysosomal export of lysine/arginine leads to retarded embryonic development reveals the role of lysosomal amino acid transporters in maintaining cytosolic amino acid availability during embryonic development, providing insights into the pathogenesis of lysosomal transport disorders.

**References and Notes**

- C. Sagné, B. Gasnier, *J. Inherit. Metab. Dis.* **31**, 258 (2008).
- W. A. Gahl, N. Bashan, F. Tietze, I. Bernardini, J. D. Schulman, *Science* **217**, 1263 (1982).
- A. J. Jonas, A. A. Greene, M. L. Smith, J. A. Schneider, *Proc. Natl. Acad. Sci. U.S.A.* **79**, 4442 (1982).
- V. Kalatzis, S. Cherqui, C. Antignac, B. Gasnier, *EMBO J.* **20**, 5940 (2001).
- J. G. Thoene, R. G. Oshima, J. C. Crawhall, D. L. Olson, J. A. Schneider, *J. Clin. Invest.* **58**, 180 (1976).
- W. A. Gahl, F. Tietze, J. D. Butler, J. D. Schulman, *Biochem. J.* **228**, 545 (1985).
- R. L. Pisoni, J. G. Thoene, H. N. Christensen, *J. Biol. Chem.* **260**, 4791 (1985).
- P. Guo, T. Hu, J. Zhang, S. Jiang, X. Wang, *Proc. Natl. Acad. Sci. U.S.A.* **107**, 18016 (2010).
- Y. C. Wu, G. M. Stanfield, H. R. Horvitz, *Genes Dev.* **14**, 536 (2000).

- J. Kimble, W. J. Sharrock, *Dev. Biol.* **96**, 189 (1983).
- B. Grant, D. Hirsh, *Mol. Biol. Cell* **10**, 4311 (1999).
- A. Audhya, I. X. McLeod, J. R. Yates, K. Oegema, *PLoS ONE* **2**, e956 (2007).
- N. Mizushima, *Genes Dev.* **21**, 2861 (2007).
- Y. Zhang *et al.*, *Cell* **136**, 308 (2009).
- Y. Tian *et al.*, *Cell* **141**, 1042 (2010).
- Y. Zhai, W. H. Heijne, D. W. Smith, M. H. Saier Jr., *Biochim. Biophys. Acta* **1511**, 206 (2001).
- P. M. Mangahas, X. Yu, K. G. Miller, Z. Zhou, *J. Cell Biol.* **180**, 357 (2008).
- T. Braulke, J. S. Bonifacio, *Biochim. Biophys. Acta* **1793**, 605 (2009).
- S. Treusch *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **101**, 4483 (2004).
- Y. Zhang, B. Grant, D. Hirsh, *Mol. Biol. Cell* **12**, 2011 (2001).
- T. E. Dever *et al.*, *Cell* **68**, 585 (1992).
- P. Syntichaki, K. Troulinaki, N. Tavernarakis, *Nature* **445**, 922 (2007).
- S. A. Wek, S. Zhu, R. C. Wek, *Mol. Cell. Biol.* **15**, 4497 (1995).
- P. Zhang *et al.*, *Mol. Cell. Biol.* **22**, 6681 (2002).

**Acknowledgments:** We thank B. Zhu and X. Wang for discussion and critical reading of the manuscript; M. Dong for antibodies; B. Grant, H. Fares, D. Xue, H. Zhang, and the C. elegans Genetic Center (CGC) for strains; the Moerman laboratory (University of British Columbia) for performing the comparative genomic hybridization array; and I. Hanson for editing services. Data described in the paper are presented in the main text and the supplementary materials. This work was supported by a Ministry of Science and Technology grant (2010CB835201) to X.W. and a CR-UK Career Development Award (C11852/A4500), a CR-UK Project Grant (C11852/A5991), and a Wellcome Trust Senior Research Fellowship (0909444/Z/09/2) to A.G.

**Supplementary Materials**

www.sciencemag.org/cgi/content/full/337/6092/351/DC1  
Materials and Methods  
Figs. S1 to S11  
References (25–43)

8 February 2012; accepted 23 May 2012  
10.1126/science.1220281